Schwartz Aharon
SEC insider (Form 3/4/5 filer). CIK 0001625184. Director at Protalix BioTherapeutics, Inc. (PLX) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Sep 3, 2026. Located in CARMIEL.
Companies Schwartz Aharon has filed insider reports for
- Protalix BioTherapeutics, Inc. (PLX): Director
- BioLineRx Ltd. (BLRX): Director
Schwartz Aharon
CIK: 0001625184
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (75.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectStock Options (Right to Buy)
17K shares- - Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectRestricted Stock Units
8.5K shares- - Sep 3, 2025PLX
Protalix BioTherapeutics, Inc.
AwardIndirect7.5K shares- - Jun 10, 2025PLX
Protalix BioTherapeutics, Inc.
PurchaseDirect129K shares at avg. $1.60$206K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 |  PLX Protalix BioTherapeutics, Inc. | Award Stock Options (Right to Buy) | 17,000 | - | - | Direct |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award Restricted Stock Units | 8,500 | - | - | Direct |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | Award | 7,500 | - | - | Indirect |
| Jun 10, 2025 | PLX Protalix BioTherapeutics, Inc. | Purchase | 129,000 | $1.60 | $205,884 | Direct |
1-4 of 4 transactions